Margoczy, R
11  results:
Search for persons X
?
 
?
2

Evolocumab is initiated in Central and Eastern Europe at Mu..:

Blaha, V ; Margoczy, R ; Petrov, I...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316339/.  , 2023
 
?
3

Optimal use of lipid-lowering therapy after acute coronary ..:

Banach M ; Penson PE ; Vrablik M...
info:eu-repo/semantics/altIdentifier/pmid/33607265.  , 2021
 
?
4

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY ..:

Banach, M ; Penson, PE ; Vrablik, M...
https://researchonline.ljmu.ac.uk/id/eprint/14494/1/OPTIMAL%20USE%20OF%20LIPID-LOWERING%20THERAPY%20AFTER%20ACUTE%20CORONARY%20SYNDROMES.pdf.  , 2021
 
?
5

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
6

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
7

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
8

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
9

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
10

Early eplerenone treatment in patients with acute ST-elevat..:

Montalescot, Gilles ; Pitt, Bertram ; Lopez de Sa, Esteban...
info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehu164.  , 2014
 
?
11

Evolocumab is initiated in Central and Eastern Europe at Mu..:

V Blaha ; R Margoczy ; I Petrov...
https://www.ecrjournal.com/articleindex/ecr.2023.18.PO19.  , 2023
 
1-11